Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase

Mehibel,Manal; Singh,Simendra; Cowen,Rachel  L.; Williams,Kaye  J.; Stratford,Ian  J.

doi:10.3892/or.2016.4555

Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase

Authors:
- Manal Mehibel
- Simendra Singh
- Rachel L. Cowen
- Kaye J. Williams
- Ian J. Stratford
View Affiliations

Affiliations: Experimental Oncology Group, Manchester Pharmacy School, University of Manchester, Manchester, UK, Hypoxia and Therapeutics Group, Manchester Pharmacy School, University of Manchester, Manchester, UK
Published online on: January 13, 2016 https://doi.org/10.3892/or.2016.4555
Pages: 1925-1932
Copyright: © Mehibel et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Banoxantrone (AQ4N) is a prototype hypoxia selective cytotoxin that is activated by haem containing reductases such as inducible nitric oxide synthase (iNOS). In the present study, we evaluate whether elevated levels of iNOS in human tumour cells will improve their sensitivity to AQ4N. Further, we examine the potential of radiation to increase cellular toxicity of AQ4N under normoxic (aerobic) and hypoxic conditions. We employed an expression vector containing the cDNA for human iNOS to transfect human fibrosarcoma HT1080 tumour cells. Alternatively, parental cells were exposed to a cytokine cocktail to induce iNOS gene expression and enzymatic activity. The cells were then treated with AQ4N alone and in combination with radiation in the presence or absence of the iNOS inhibitor N-methyl-L‑arginine. In parental cells, AQ4N showed little difference in toxicity under hypoxic verses normoxic conditions. Notably, cells with upregulated iNOS activity showed a significant increase in sensitivity to AQ4N, but only under conditions of reduced oxygenation. When these cells were exposed to the combination of AQ4N and radiation, there was much greater cell killing than that observed with either modality alone. In the clinical development of hypoxia selective cytotoxins it is likely they will be used in combination with radiotherapy. In the present study, we demonstrated that AQ4N can selectively kill hypoxic cells via an iNOS-dependent mechanism. This hypoxia-selective effect can be augmented by combining AQ4N with radiation without increasing cytotoxicity to well‑oxygenated tissues. Collectively, these results suggest that targeting hypoxic tumours with high levels of iNOS with a combination of AQ4N and radiotherapy could be a useful clinical therapeutic strategy.

View Figures

View References

1	Brown JM: Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today. 6:157–162. 2000. View Article : Google Scholar : PubMed/NCBI
2	Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
3	Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J radiat Oncol Biol Phys. 38:285–289. 1997. View Article : Google Scholar : PubMed/NCBI
4	Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G and Knox SJ: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 72:2600–2608. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, et al: Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res. 16:4946–4957. 2010. View Article : Google Scholar : PubMed/NCBI
6	Smith P: Cytomics of the tumour microenvironment: Therapeutic targeting. J Inflamm. 12(Suppl 1): O102015. View Article : Google Scholar
7	McKeown SR, Cowen RL and Williams KJ: Bioreductive drugs: From concept to clinic. Clin Oncol (R Coll Radiol). 19:427–442. 2007. View Article : Google Scholar
8	Mehibel M, Singh S, Chinje EC, Cowen RL and Stratford IJ: Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol Cancer Ther. 8:1261–1269. 2009. View Article : Google Scholar : PubMed/NCBI
9	McKeown SR, Hejmadi MV, Mcintyre IA, McAleer JJ and Patterson LH: AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer. 72:76–81. 1995. View Article : Google Scholar : PubMed/NCBI
10	Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, Telfer BA, Dunk CR, Harris PA and Stratford IJ: In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther. 8:3266–3275. 2009. View Article : Google Scholar : PubMed/NCBI
11	Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, Mcintyre IA, Patterson LH, Hirst DG and McKeown SR: Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer. 82:1469–1473. 2000. View Article : Google Scholar : PubMed/NCBI
12	Patterson LH and McKeown SR: AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br J Cancer. 83:1589–1593. 2000. View Article : Google Scholar : PubMed/NCBI
13	Mccarthy HO, Yakkundi A, Mcerlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR and Robson T: Bioreductive GDEPT using cytochrome P 450 3A4 in combination with AQ4N. Cancer Gene Ther. 10:40–48. 2003. View Article : Google Scholar
14	Mcerlane V, Yakkundi A, Mccarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T and McKeown SR: A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med. 7:851–859. 2005. View Article : Google Scholar : PubMed/NCBI
15	Rooseboom M, Commandeur JN and Vermeulen NP: Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 56:53–102. 2004. View Article : Google Scholar : PubMed/NCBI
16	Nishida CR and Ortiz de Montellano PR: Reductive heme-dependent activation of the N-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem. 51:5118–5120. 2008. View Article : Google Scholar : PubMed/NCBI
17	Fitzpatrick B, Mehibel M, Cowen RL and Stratford IJ: iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide. 19:217–224. 2008. View Article : Google Scholar : PubMed/NCBI
18	Cobbs CS, Brenman JE, Aldape KD, Bredt DS and Israel MA: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55:727–730. 1995.PubMed/NCBI
19	Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 90:587–596. 1998. View Article : Google Scholar : PubMed/NCBI
20	Hemmens B and Mayer B: Enzymology of nitric oxide synthases. Methods Mol Biol. 100:1–32. 1998.
21	Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR and Snyder SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 351:714–718. 1991. View Article : Google Scholar : PubMed/NCBI
22	Griffith OW and Stuehr DJ: Nitric oxide synthases: Properties and catalytic mechanism. Annu Rev Physiol. 57:707–736. 1995. View Article : Google Scholar : PubMed/NCBI
23	Gray LH, Green FO and Hawes CA: Effect of nitric oxide on the radiosensitivity of tumour cells. Nature. 182:952–953. 1958. View Article : Google Scholar : PubMed/NCBI
24	Singh S, Cowen RL, Chinje EC and Stratford IJ: The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells. Radiat Res. 171:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
25	Chinje EC, Williams KJ, Telfer BA, Wood PJ, van der Kogel AJ and Stratford IJ: 17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer. 86:136–142. 2002. View Article : Google Scholar : PubMed/NCBI
26	Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL and Stratford IJ: Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol. 63:1248–1255. 2003. View Article : Google Scholar : PubMed/NCBI
27	Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL and Stratford IJ: Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer. 72:1144–1150. 1995. View Article : Google Scholar : PubMed/NCBI
28	Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI
29	Trédan O, Garbens AB, Lalani AS and Tannock IF: The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 69:940–947. 2009. View Article : Google Scholar : PubMed/NCBI
30	Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, et al: Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study. Clin Cancer Res. 14:1096–1104. 2008. View Article : Google Scholar : PubMed/NCBI
31	Manley E Jr and Waxman DJ: Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 344:368–377. 2013. View Article : Google Scholar :
32	Patterson LH: Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Metastasis Rev. 12:119–134. 1993. View Article : Google Scholar : PubMed/NCBI
33	Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, Wilson WR, Dachs GU and Patterson AV: Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol Pharmacol. 81:31–40. 2012. View Article : Google Scholar
34	Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA and Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol. 161:630–634. 1999. View Article : Google Scholar : PubMed/NCBI
35	Song ZJ, Gong P and Wu YE: Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol. 8:591–595. 2002. View Article : Google Scholar : PubMed/NCBI
36	Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F and Qian F: Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg. 67:709–713. 2001.PubMed/NCBI
37	Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
38	Howard-Flanders P: Effect of nitric oxide on the radiosensitivity of bacteria. Nature. 180:1191–1192. 1957. View Article : Google Scholar : PubMed/NCBI
39	Griffin RJ, Makepeace CM, Hur WJ and Song CW: Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J radiat Oncol Biol Phys. 36:377–383. 1996. View Article : Google Scholar : PubMed/NCBI
40	Mitchell JB, Cook JA, Krishna MC, DeGraff W, Gamson J, Fisher J, Christodoulou D and Wink DA: Radiation sensitisation by nitric oxide releasing agents. Br J Cancer Suppl. 27:S181–S184. 1996.PubMed/NCBI
41	Verovski VN, Van den Berge DL, Soete GA, Bols BL and Storme GA: Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer. 74:1734–1742. 1996. View Article : Google Scholar : PubMed/NCBI